Although BCL2 was increased in response to lapatinib, BCL2 levels were decreased upon trastuzumab exposure, consistent with previous studies.45 Despite the well-documented oncogenic role for BCL2 in hematological malignancies, its expression is correlates with a favorable patient outcome in breast cancer.46 The gene discussed is BCL2; the disease is hematologic disorder.